301258 Stock Overview
Engages in the manufacture and sale of biopharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Suzhou Fushilai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥27.19 |
| 52 Week High | CN¥43.39 |
| 52 Week Low | CN¥19.63 |
| Beta | 0.53 |
| 11 Month Change | -1.88% |
| 3 Month Change | 28.44% |
| 1 Year Change | -21.85% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.13% |
Recent News & Updates
Shareholder Returns
| 301258 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.5% | -0.6% | -2.8% |
| 1Y | -21.8% | -8.7% | 2.0% |
Return vs Industry: 301258 underperformed the CN Pharmaceuticals industry which returned -8.7% over the past year.
Return vs Market: 301258 underperformed the CN Market which returned 2% over the past year.
Price Volatility
| 301258 volatility | |
|---|---|
| 301258 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 301258 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301258's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 544 | Xiangyun Qian | www.fuslai.com |
Suzhou Fushilai Pharmaceutical Co., Ltd. engages in the manufacture and sale of biopharmaceutical products in China. It primarily focuses on manufacturing Alpha Lipoic Acid, L-Carnosine, and Phosphatidylcholine series of products. Its products are primarily used in medicines, dietary supplements, cosmetics, and other fields.
Suzhou Fushilai Pharmaceutical Co., Ltd. Fundamentals Summary
| 301258 fundamental statistics | |
|---|---|
| Market cap | CN¥2.47b |
| Earnings (TTM) | CN¥18.88m |
| Revenue (TTM) | CN¥413.15m |
131.3x
P/E Ratio6.0x
P/S RatioIs 301258 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301258 income statement (TTM) | |
|---|---|
| Revenue | CN¥413.15m |
| Cost of Revenue | CN¥325.13m |
| Gross Profit | CN¥88.02m |
| Other Expenses | CN¥69.15m |
| Earnings | CN¥18.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 21.31% |
| Net Profit Margin | 4.57% |
| Debt/Equity Ratio | 0% |
How did 301258 perform over the long term?
See historical performance and comparison